

**Fonte: PubMed  
(ultimo accesso: 8 agosto 2015)**

- 1: Bonotto M, Puglisi F. [Early breast cancer in pre-menopausal women and endocrine treatment: which factors impact on decision-making process?]. *Recenti Prog Med.* 2015 Aug;106(8):364-9. doi: 10.1701/1960.21300. Italian. PubMed PMID: 26228859.
  
- 2: Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. *Oncologist.* 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22. PubMed PMID: 26099741.
  
- 3: Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. *Lancet Oncol.* 2015 Jul;16(7):848-58. doi: 10.1016/S1470-2045(15)00049-2. Epub 2015 Jun 16. PubMed PMID: 26092816.
  
- 4: Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, Puglisi F. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines? *Oncologist.* 2015 Jul;20(7):719-24. doi: 10.1634/theoncologist.2015-0002. Epub 2015 May 27. PubMed PMID: 26018662.
  
- 5: Baldan F, Mio C, Lavarone E, Di Loreto C, Puglisi F, Damante G, Puppini C. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells. *Oncol Rep.* 2015 May;33(5):2199-206. doi: 10.3892/or.2015.3873. Epub 2015 Mar 23. PubMed PMID: 25812606.
  
- 6: Molinari C, Clauser P, Girometti R, Linda A, Cimino E, Puglisi F, Zuiani C, Bazzocchi M. MR mammography using diffusion-weighted imaging in evaluating breast cancer: a correlation with proliferation index. *Radiol Med.* 2015 Mar 17. [Epub

ahead of print] PubMed PMID: 25776017.

7: Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. *Lancet*. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2. PubMed PMID: 25740286.

8: Mustacchi G, Puglisi F, Molino AM, Crivellari D, Ghiotto C, Ferro A, Brunello A, Saracchini S, Turazza M, Cretella E, Iop A, Malagoli M, Stefani M. Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients. *Future Oncol*. 2015;11(10):1493-500. doi: 10.2217/fon.15.34. Epub 2015 Feb 24. PubMed PMID: 25708426.

9: Bonotto M, Fontanella C, Puglisi F. Looking for predictive markers in breast cancer. *Lancet Oncol*. 2015 Jan;16(1):e1. doi: 10.1016/S1470-2045(14)71107-6. Epub 2014 Dec 29. PubMed PMID: 25638542.

10: Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, Puglisi F. Pattern of metastasis and outcome in patients with breast cancer. *Clin Exp Metastasis*. 2015 Feb;32(2):125-33. doi: 10.1007/s10585-015-9697-2. Epub 2015 Jan 29. PubMed PMID: 25630269.

11: Guarneri V, Dieci MV, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P. Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. *Ann Surg Oncol*. 2015 Jan 9. [Epub ahead of print] PubMed PMID: 25572687.

12: Fontanella C, Aita M, Cinausero M, Aprile G, Baldin MG, Dusi V, Lestuzzi C, Fasola G, Puglisi F. Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart? *Onco Targets Ther*. 2014 Sep 29;7:1783-91. doi: 10.2147/OTT.S65653. eCollection 2014. PubMed PMID: 25302025; PubMed Central PMCID: PMC4189715.

13: von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with

bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28. PubMed PMID: 25273342.

14: Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med.* 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. PubMed PMID: 24881463; PubMed Central PMCID: PMC4175521.

15: Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andretta C, Mansutti M, Pisa FE, Fasola G, Puglisi F. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. *Oncologist.* 2014 Jun;19(6):608-15. doi: 10.1634/theoncologist.2014-0002. Epub 2014 May 2. PubMed PMID: 24794159; PubMed Central PMCID: PMC4041678.

16: Foltran L, Aprile G, Pisa FE, Ermacora P, Pella N, Iaiza E, Poletto E, Lutrino SE, Mazzer M, Giovannoni M, Cardellino GG, Puglisi F, Fasola G. Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. *Support Care Cancer.* 2014 Sep;22(9):2527-33. doi: 10.1007/s00520-014-2234-z. Epub 2014 Apr 13. PubMed PMID: 24728616.

17: Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, Gori S, Del Mastro L. Follow-up of patients with early breast cancer: is it time to rewrite the story? *Crit Rev Oncol Hematol.* 2014 Aug;91(2):130-41. doi: 10.1016/j.critrevonc.2014.03.001. Epub 2014 Mar 22. Review. PubMed PMID: 24726438.

18: Pedrazzoli P, Baldanti F, Donatelli I, Castrucci MR, Puglisi F, Silvestris N, Cinieri S; Italian Society of Medical Oncology. Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). *Ann Oncol.* 2014 Jun;25(6):1243-7. doi: 10.1093/annonc/mdu114. Epub 2014 Mar 11. PubMed PMID: 24618150.

19: Sini V, Lunardi G, Cirillo M, Turazza M, Bighin C, Giraudi S, Levaggi A, Piccioli P, Bisagni G, Gnoni R, Stridi G, Porpiglia M, Picardo E, Ponzzone R, Marengo D, Mansutti M, Puglisi F, Del Mastro L. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. *Br J Cancer.* 2014 Mar 4;110(5):1133-8. doi: 10.1038/bjc.2014.2. Epub 2014 Jan 21. PubMed PMID:

24448359; PubMed Central PMCID: PMC3950872.

20: Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. *World J Gastroenterol*. 2013 Dec 14;19(46):8474-88. doi: 10.3748/wjg.v19.i46.8474. Review. PubMed PMID: 24379565; PubMed Central PMCID: PMC3870493.

21: Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. *Endocr Relat Cancer*. 2014 Jan 21;21(1):R51-65. doi: 10.1530/ERC-13-0335. Print 2014 Feb. Review. PubMed PMID: 24292601.

22: Bozza C, Osa EO, Puglisi F. Primary therapy in breast cancer: what have we learned from landmark trials? *Womens Health (Lond Engl)*. 2013 Nov;9(6):583-93. doi: 10.2217/whe.13.55. Review. PubMed PMID: 24161310.

23: Russo S, Cinausero M, Gerratana L, Bozza C, Iacono D, Driol P, Deroma L, Sottile R, Fasola G, Puglisi F. Factors affecting patient's perception of anticancer treatments side-effects: an observational study. *Expert Opin Drug Saf*. 2014 Feb;13(2):139-50. doi: 10.1517/14740338.2013.830710. Epub 2013 Sep 27. PubMed PMID: 24073801.

24: Pegolo E, Puppini C, Gerometta A, Damante G, Puglisi F, Di Loreto C. One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis. *Virchows Arch*. 2013 Jul;463(1):7-15. doi: 10.1007/s00428-013-1440-2. Epub 2013 Jun 19. PubMed PMID: 23779101.

25: Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, Guardascione M, Fontanella C, Fasola G, Puglisi F. Risk factors and survival outcomes in patients with brain metastases from breast cancer. *Clin Exp Metastasis*. 2013 Dec;30(8):951-6. doi: 10.1007/s10585-013-9594-5. Epub 2013 Jun 18. PubMed PMID: 23775210.

26: Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Lunardi G, Venturini M; AIOM Working Group "Interaction with Regional Sections" (2009-2011). Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society

of Medical Oncology (AIOM). Tumori. 2013 Jan-Feb;99(1):35-8. doi: 10.1700/1248.13785. PubMed PMID: 23548997.

27: Arpino G, Generali D, Sapino A, Del Matro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L. Gene expression profiling in breast cancer: a clinical perspective. Breast. 2013 Apr;22(2):109-20. doi: 10.1016/j.breast.2013.01.016. Epub 2013 Feb 23. Review. PubMed PMID: 23462680.

28: Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribí K, Price KN, Láng I, Gianni L, Spazzapan S, Pinotti G, Lüthi JM, Gelber RD, Regan MM, Colleoni M, Castiglione-Gertsch M, Maibach R, Rabaglio M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast. 2013 Apr;22(2):130-7. doi: 10.1016/j.breast.2013.01.015. Epub 2013 Feb 28. PubMed PMID: 23453899; PubMed Central PMCID: PMC3613787.

29: Minisini AM, Pascoletti G, Intersimone D, Poletto E, Driol P, Spizzo R, Scott CA, Puglisi F, Fasola G, Di Loreto C. Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma. Melanoma Res. 2013 Apr;23(2):96-101. doi: 10.1097/CMR.0b013e32835e7734. PubMed PMID: 23411479.

30: Aprile G, Ferrari L, Fontanella C, Puglisi F. Bevacizumab in older patients with advanced colorectal or breast cancer. Crit Rev Oncol Hematol. 2013 Jul;87(1):41-54. doi: 10.1016/j.critrevonc.2012.11.006. Epub 2012 Dec 20. Review. PubMed PMID: 23265855.

31: Bonotto M, Bozza C, Di Loreto C, Osa EO, Poletto E, Puglisi F. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase? Clin Breast Cancer. 2013 Jun;13(3):167-72. doi: 10.1016/j.clbc.2012.10.002. Epub 2012 Dec 5. Review. PubMed PMID: 23218471.

32: Di Maio M, Bria E, Banna GL, Puglisi F, Garassino MC, Lorusso D, Perrone F. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anticancer Drugs. 2013 Feb;24(2):99-111. doi: 10.1097/CAD.0b013e328359d7ba. Review. PubMed PMID: 23165435.

33: Lunardi G, Piccioli P, Bruzzi P, Notaro R, Lastraioli S, Serra M, Marroni P, Bighin C, Mansutti M, Puglisi F, Porpiglia M, Ponzzone R, Bisagni G, Garrone O,

Cavazzini G, Clavarezza M, Del Mastro L. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. *Breast Cancer Res Treat.* 2013 Jan;137(1):167-74. doi: 10.1007/s10549-012-2306-z. Epub 2012 Nov 6. PubMed PMID: 23129173; PubMed Central PMCID: PMC3528956.

34: Poletto M, Di Loreto C, Marasco D, Poletto E, Puglisi F, Damante G, Tell G. Acetylation on critical lysine residues of Apurinic/aprimidinic endonuclease 1 (APE1) in triple negative breast cancers. *Biochem Biophys Res Commun.* 2012 Jul 20;424(1):34-9. doi: 10.1016/j.bbrc.2012.06.039. Epub 2012 Jun 16. PubMed PMID: 22713458.

35: Puglisi F, Minisini AM, De Angelis C, Arpino G. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. *Drugs.* 2012 Jun 18;72(9):1175-93. doi: 10.2165/11634000-000000000-00000. Review. PubMed PMID: 22686613.

36: Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. *Breast Cancer Res Treat.* 2012 Jul;134(1):283-9. doi: 10.1007/s10549-012-2045-1. Epub 2012 Apr 4. PubMed PMID: 22476856.

37: Passon N, Gerometta A, Puppini C, Lavarone E, Puglisi F, Tell G, Di Loreto C, Damante G. Expression of Dicer and Drosha in triple-negative breast cancer. *J Clin Pathol.* 2012 Apr;65(4):320-6. doi: 10.1136/jclinpath-2011-200496. Epub 2012 Jan 18. PubMed PMID: 22259182.

38: Federico E, Falconi M, Zuodar G, Falconieri G, Puglisi F. B-cell lymphoma presenting as acute pancreatitis. *Pancreatology.* 2011;11(6):553-6. doi: 10.1159/000332038. Epub 2011 Dec 27. PubMed PMID: 22205036.

39: Miscoria M, Tonetto F, Deroma L, Machin P, Di Loreto C, Driol P, Minisini AM, Russo S, Andretta C, Mansutti M, Damante G, Fasola G, Puglisi F. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. *Anticancer Drugs.* 2012 Mar;23(3):326-34. doi: 10.1097/CAD.0b013e32834e735a. PubMed PMID: 22129512.

40: Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives.

Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177.  
Review. PubMed PMID: 22124364.

41: Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M; AIOM Working Group "Interactions with Regional Sections" (2009-2011). Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori. 2011 Jul-Aug;97(4):442-8. doi: 10.1700/950.10395. PubMed PMID: 21989431.

42: Puppini C, Puglisi F, Pandolfi M, Di Loreto C, Damante G. Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines. Oncol Rep. 2011 Aug;26(2):309-14. doi: 10.3892/or.2011.1310. Epub 2011 May 20. PubMed PMID: 21617864.

43: Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011 May 12;30:54. doi: 10.1186/1756-9966-30-54. PubMed PMID: 21569417; PubMed Central PMCID: PMC3120715.

44: Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M; AIOM Working Group Interaction with Regional Sections (2007-2009). Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). Tumori. 2010 Nov-Dec;96(6):1010-5. PubMed PMID: 21388067.

45: Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24. PubMed PMID: 20498403.

46: Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, Del Mastro

L. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. *Breast*. 2010 Oct;19(5):333-8. doi: 10.1016/j.breast.2010.01.018. Epub 2010 Feb 24. PubMed PMID: 20185313.

47: Puglisi F, Minisini AM. Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? *Crit Rev Oncol Hematol*. 2011 Feb;77(2):87-99. doi: 10.1016/j.critrevonc.2010.01.006. Epub 2010 Feb 4. Review. PubMed PMID: 20133149.

48: Andretta C, Minisini AM, Miscoria M, Puglisi F. First-line chemotherapy with or without biologic agents for metastatic breast cancer. *Crit Rev Oncol Hematol*. 2010 Nov;76(2):99-111. doi: 10.1016/j.critrevonc.2010.01.007. Epub 2010 Jan 22. Review. PubMed PMID: 20097088.

49: Puglisi F. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. *Cancer*. 2010 Jan 15;116(2):538; author reply 538-9. doi: 10.1002/cncr.24826. PubMed PMID: 19950132.

50: Puglisi F. What does similarity mean in clinical trials? *J Clin Oncol*. 2009 Nov 20;27(33):e205; author reply e206. doi: 10.1200/JCO.2009.23.9467. Epub 2009 Oct 26. PubMed PMID: 19858381.

51: Della Mea V, De Momi I, Aprile G, Puglisi F, Menis J, Casetta A, Bolzonello S, Fasola G. Feasibility study of a web application for self-report of anticancer treatment toxicities. *Stud Health Technol Inform*. 2009;150:562-6. PubMed PMID: 19745374.

52: Crivellari D, Spazzapan S, Puglisi F, Fratino L, Scalone S, Veronesi A. Hormone therapy in elderly breast cancer patients with comorbidities. *Crit Rev Oncol Hematol*. 2010 Jan;73(1):92-8. doi: 10.1016/j.critrevonc.2009.02.003. Epub . Review. PubMed PMID: 19349190.

53: Minisini AM, Menis J, Valent F, Andretta C, Alessi B, Pascoletti G, Piga A, Fasola G, Puglisi F. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. *Anticancer Drugs*. 2009 Jul;20(6):503-7. doi: 10.1097/CAD.0b013e3283243df3. PubMed PMID: 19339872.

54: Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. *Anticancer*



Drugs. 2009 Apr;20(4):217-29. doi: 10.1097/CAD.0b013e3283293fd4. Review. PubMed PMID: 19247178.

55: Aprile G, Belvedere O, Puglisi F. From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. *Anticancer Drugs*. 2008 Nov;19(10):941-56. doi: 10.1097/CAD.0b013e328317ee58. Review. PubMed PMID: 18827559.

56: Puglisi F, Deroma L, Russo S, Carteni G, Sporchia A, Ucci G, De Signoribus G, Del Prete S, Vecchione A, Pinotti G, Beccaglia P. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. *Crit Rev Oncol Hematol*. 2009 Feb;69(2):175-82. doi: 10.1016/j.critrevonc.2008.07.010. Epub 2008 Sep 6. PubMed PMID: 18774730.

57: Andretta C, Puppini C, Minisini A, Valent F, Pegolo E, Damante G, Di Loreto C, Pizzolitto S, Pandolfi M, Fasola G, Piga A, Puglisi F. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. *Ann Oncol*. 2009 Feb;20(2):265-71. doi: 10.1093/annonc/mdn592. Epub 2008 Sep 2. PubMed PMID: 18765464.

58: Puglisi F, Cardellino GG, Crivellari D, Di Loreto C, Magri MD, Minisini AM, Mansutti M, Andretta C, Russo S, Lombardi D, Perin T, Damante G, Veronesi A. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. *Ann Oncol*. 2008 Sep;19(9):1541-6. doi: 10.1093/annonc/mdn165. Epub 2008 Apr 25. PubMed PMID: 18441329.

59: Minisini AM, De Faccio S, Ermacora P, Andretta C, Fantinel R, Balestrieri M, Piga A, Puglisi F. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. *Crit Rev Oncol Hematol*. 2008 Jul;67(1):71-9. doi: 10.1016/j.critrevonc.2008.02.004. Epub 2008 Apr 3. PubMed PMID: 18394917.

60: Minisini AM, Andretta C, Fasola G, Puglisi F. Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer. *Expert Rev Anticancer Ther*. 2008 Mar;8(3):331-42. doi: 10.1586/14737140.8.3.331. Review. PubMed PMID: 18366282.

61: Bracci R, Zanon E, Cellerino R, Gesuita R, Puglisi F, Aprile G, Barbieri V, Misuraca D, Venuta S, Carle F, Piga A. Information to cancer patients: a questionnaire survey in three different geographical areas in Italy. *Support Care Cancer*. 2008 Aug;16(8):869-77. doi: 10.1007/s00520-007-0375-z. Epub 2008 Jan 26. PubMed PMID: 18224349.

62: Puglisi F, Aprile G, Fasola G. Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology. *Anticancer Drugs*. 2008 Feb;19(2):221-33. doi: 10.1097/CAD.0b013e3282f2c938. PubMed PMID: 18176120.

63: Puglisi F, Puppini C, Pegolo E, Andretta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, Di Loreto C. Expression of periostin in human breast cancer. *J Clin Pathol*. 2008 Apr;61(4):494-8. Epub 2007 Oct 15. PubMed PMID: 17938160.

64: Puglisi F, Andretta C, Valent F, Minisini AM, Rijavec E, Russo S, Mansutti M, Cardellino G, Pizzolitto S, Di Loreto C. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. *Anticancer Drugs*. 2007 Sep;18(8):883-8. PubMed PMID: 17667593.

65: Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andretta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. *Breast Cancer Res Treat*. 2008 Jul;110(1):127-34. Epub 2007 Aug 9. PubMed PMID: 17687648.

66: Minisini AM, Fabbro D, Di Loreto C, Pestrin M, Russo S, Cardellino GG, Andretta C, Damante G, Puglisi F. Markers of the uPA system and common prognostic factors in breast cancer. *Am J Clin Pathol*. 2007 Jul;128(1):112-7. PubMed PMID: 17580278.

67: Del Frate C, Borghese L, Cedolini C, Bestagno A, Puglisi F, Isola M, Soldano F, Bazzocchi M. Role of pre-surgical breast MRI in the management of invasive breast carcinoma. *Breast*. 2007 Oct;16(5):469-81. Epub 2007 Apr 12. PubMed PMID: 17433681.

68: Carteni G, Giannetta L, Ucci G, De Signoribus G, Vecchione A, Pinotti G, Puglisi F, Contillo A, Pezzella G, Orecchia S, Beccaglia P; OBI/EPO-ITA-01/1 study group. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. *Support Care Cancer*. 2007 Sep;15(9):1057-66. Epub 2007 Apr 13. PubMed PMID: 17431689.

69: Zuiani C, Mazzarella F, Londero V, Linda A, Puglisi F, Bazzocchi M. Stereotactic vacuum-assisted breast biopsy: results, follow-up and correlation

with radiological suspicion. *Radiol Med.* 2007 Mar;112(2):304-17. Epub 2007 Mar 19. English, Italian. PubMed PMID: 17361368.

70: Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. *Eur J Cancer.* 2007 Feb;43(3):497-509. Epub 2007 Jan 12. Review. PubMed PMID: 17223541.

71: Fasola G, Puglisi F, Follador A, Aita M, Di Terlizzi S, Belvedere O. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report. *BMC Cancer.* 2006 Dec 18;6:289. PubMed PMID: 17176466; PubMed Central PMCID: PMC1764904.

72: Puglisi F, Andretta C, Fasola G. Highlights from the 42nd annual meeting of the American Society of Clinical Oncology Atlanta, GA, USA, 2-6 June 2006. *Expert Opin Pharmacother.* 2006 Nov;7(16):2309-18. PubMed PMID: 17059386.

73: Del Frate C, Bestagno A, Cerniati R, Soldano F, Isola M, Puglisi F, Bazzocchi M. Sonographic criteria for differentiation of benign and malignant solid breast lesions: size is of value. *Radiol Med.* 2006 Sep;111(6):783-96. Epub 2006 Aug 11. English, Italian. PubMed PMID: 16896562.

74: Puppini C, Puglisi F, Pellizzari L, Manfioletti G, Pestrin M, Pandolfi M, Piga A, Di Loreto C, Damante G. HEX expression and localization in normal mammary gland and breast carcinoma. *BMC Cancer.* 2006 Jul 19;6:192. PubMed PMID: 16854221; PubMed Central PMCID: PMC1550255.

75: de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A. Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). *Crit Rev Oncol Hematol.* 2006 Jul;59(1):40-50. Epub 2006 Apr 4. Review. PubMed PMID: 16600618.

76: Zuiani C, Londero V, Bestagno A, Puglisi F, Di Loreto C, Bazzocchi M. Proliferative high-risk lesions of the breast: contribution and limits of US-guided core biopsy. *Radiol Med.* 2005 Nov-Dec;110(5-6):589-602. English, Italian. PubMed PMID: 16437044.

77: Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. *Breast Cancer Res Treat.* 2006 Jan;95(1):45-53. PubMed PMID: 16267615.

78: Puglisi F, Piccart M. Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story? *Onkologie*. 2005 Nov;28(11):547-9. PubMed PMID: 16249638.

79: Puglisi F, de Azambuja E, de Castro G Jr, Demonty G. Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma. *J Clin Oncol*. 2005 Sep 20;23(27):6803-4; author reply 6804-5. Erratum in: *J Clin Oncol*. 2005 Dec 20;23(36):9445. PubMed PMID: 16170195.

80: Minisini AM, Di Loreto C, Mansutti M, Artico D, Pizzolitto S, Piga A, Puglisi F. Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. *Cancer Lett*. 2005 Jun 16;224(1):133-9. Epub 2004 Dec 13. PubMed PMID: 15911109.

81: Di Loreto C, Tell G, Pestrin M, Pandolfi M, Damante G, Puglisi F. PTEN and Egr-1 expression in thyroid proliferative lesions. *Cancer Lett*. 2005 Jun 16;224(1):105-9. Epub 2004 Nov 23. PubMed PMID: 15911105.

82: Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andreetta C, Di Terlizzi S, Piga A. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. *Ann Oncol*. 2005 Feb;16(2):263-6. PubMed PMID: 15668281.

83: Guglielmi A, Barni S, Zaniboni A, Pella N, Belvedere O, Beretta GD, Grossi F, Frontini L, Puglisi F, Labianca R, Sobrero A; Gruppo Italiano Studio Carcinomi Apparato Digerente. Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. *Br J Cancer*. 2004 Oct 18;91(8):1428-33. PubMed PMID: 15381935; PubMed Central PMCID: PMC2409920.

84: Puglisi F, Federico E. D-dimer and venous thromboembolism. *Ann Intern Med*. 2004 Sep 21;141(6):482-3; author reply 483. PubMed PMID: 15381528.

85: Grossi F, Belvedere O, Fasola G, Barbone F, Rizzato S, Sibau A, Recchia L, Vigevani E, Ceschia T, Morelli A, Guglielmi A, Puglisi F, Follador A, Talmassons G, Sobrero AF. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). *Lung Cancer*. 2004 Oct;46(1):99-106. PubMed PMID: 15364137.

86: Puglisi F, Mansutti M, Aprile G, Minisini AM, Di Loreto C, Bazzocchi M, Londero V, Cedolini C, Gentile G, Pizzolitto S, Piga A, Sobrero A. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer. *Anticancer Res.* 2004 Jul-Aug;24(4):2487-93. PubMed PMID: 15330203.

87: Puglisi F, Minisini AM, Barbone F, Intersimone D, Aprile G, Puppini C, Damante G, Paron I, Tell G, Piga A, Di Loreto C. Galectin-3 expression in non-small cell lung carcinoma. *Cancer Lett.* 2004 Aug 30;212(2):233-9. PubMed PMID: 15279903.

88: Puglisi F. Bone scanning in lung cancer: pretest probability is of value. *BMJ.* 2004 Jul 24;329(7459):231. PubMed PMID: 15271843; PubMed Central PMCID: PMC487746.

89: Casarsa S, Puglisi F, Baudi F, De Paola L, Venuta S, Piga A, Di Loreto C, Marchesoni D, D'Elia AV, Damante G. BRCA2 germline mutations in primary cancer of the fallopian tube. *Oncol Rep.* 2004 Aug;12(2):313-6. PubMed PMID: 15254695.

90: Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L. What is the effect of systemic anticancer treatment on cognitive function? *Lancet Oncol.* 2004 May;5(5):273-82. Review. PubMed PMID: 15120664.

91: Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. *Eur Radiol.* 2004 Aug;14(8):1371-9. Epub 2004 Feb 18. PubMed PMID: 14986052.

92: Bisca A, D'Ambrosio C, Scaloni A, Puglisi F, Aprile G, Piga A, Zuiani C, Bazzocchi M, Di Loreto C, Paron I, Tell G, Damante G. Proteomic evaluation of core biopsy specimens from breast lesions. *Cancer Lett.* 2004 Feb 10;204(1):79-86. PubMed PMID: 14744537.

93: Puglisi F, Zuiani C, Bazzocchi M, Valent F, Aprile G, Pertoldi B, Minisini AM, Cedolini C, Londero V, Piga A, Di Loreto C. Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions. *Oncology.* 2003;65(4):311-5. PubMed PMID: 14707450.

94: Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C, Sobrero A. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in

advanced colorectal cancer. *Ann Oncol.* 2004 Jan;15(1):55-8. PubMed PMID: 14679120.

95: Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, Puglisi F. Taxane-induced nail changes: incidence, clinical presentation and outcome. *Ann Oncol.* 2003 Feb;14(2):333-7. PubMed PMID: 12562663.

96: Puglisi F, Minisini AM, Aprile G, Barbone F, Cataldi P, Artico D, Damante G, Beltrami CA, Di Loreto C. Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer. *Oncology.* 2002;63(1):76-83. PubMed PMID: 12187075.

97: Puglisi F, Aprile G, Minisini AM, Barbone F, Cataldi P, Tell G, Kelley MR, Damante G, Beltrami CA, Di Loreto C. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. *Anticancer Res.* 2001 Nov-Dec;21(6A):4041-9. PubMed PMID: 11911289.

98: D'Elia AV, Tell G, Russo D, Arturi F, Puglisi F, Manfioletti G, Gattei V, Mack DL, Cataldi P, Filetti S, Di Loreto C, Damante G. Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors. *J Clin Endocrinol Metab.* 2002 Mar;87(3):1376-83. PubMed PMID: 11889211.

99: Puglisi F, Barbone F, Tell G, Aprile G, Pertoldi B, Raiti C, Kelley MR, Damante G, Sobrero A, Beltrami CA, Di Loreto C. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. *Oncol Rep.* 2002 Jan-Feb;9(1):11-7. PubMed PMID: 11748448.

100: Bazzocchi M, Berra I, Francescutti GE, Del Frate C, Zuiani C, Puglisi F, Di Loreto C. [Papillary lesions of the breast: diagnostic imaging and contribution of percutaneous needle biopsy with 14G needle]. *Radiol Med.* 2001 Jun;101(6):424-31. Italian. PubMed PMID: 11479438.

101: Puglisi F, Aprile G, Sobrero A. Tamoxifen-induced total alopecia. *Ann Intern Med.* 2001 Jun 19;134(12):1154-5. PubMed PMID: 11412069.

102: Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, Grossi F. Fatigue: a main component of anemia symptomatology. *Semin Oncol.* 2001 Apr;28(2 Suppl 8):15-8. Review. PubMed PMID: 11395847.

103: Bazzocchi M, Facecchia I, Zuiani C, Puglisi F, Di Loreto C, Smania S.

[Diagnostic imaging of lobular carcinoma of the breast: mammographic, ultrasonographic and MR findings]. *Radiol Med.* 2000 Dec;100(6):436-43. Italian. PubMed PMID: 11307504.

104: Puglisi F, Aprile G, Bruckbauer M, Barbone F, Damante G, Guerra S, Beltrami CA, Di Loreto C. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. *Cancer Lett.* 2001 Jan 10;162(1):97-103. PubMed PMID: 11121867.

105: Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. *Semin Oncol.* 2000 Oct;27(5 Suppl 10):72-7. Review. PubMed PMID: 11049035.

106: Puglisi F, Federico E, Pertoldi B, Guerra S. Clinicians, diagnosis and clinical decision making: the importance of an evidence based approach. Part I. Introduction to evidence based medicine and how to search for it. *Adv Clin Path.* 2000 Jan;4(1):3-10. Review. PubMed PMID: 10936893.

107: Tell G, Pellizzari L, Pucillo C, Puglisi F, Cesselli D, Kelley MR, Di Loreto C, Damante G. TSH controls Ref-1 nuclear translocation in thyroid cells. *J Mol Endocrinol.* 2000 Jun;24(3):383-90. PubMed PMID: 10828831.

108: Puglisi F, Cesselli D, Damante G, Pellizzari L, Beltrami CA, Di Loreto C. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases. *Anticancer Res.* 2000 Jan-Feb;20(1A):311-6. PubMed PMID: 10769673.

109: Mercuri F, Giacomello R, Puglisi F, Colaone R, Fabbro D, Menegon MG, Ceriello A, Gonano F, Damante G. Factor V leiden increases plasma F1+2 levels both in normal and deep venous thrombosis subjects. *Haematologica.* 2000 Apr;85(4):386-9. PubMed PMID: 10756364.

110: Puglisi F, Pertoldi B, Ramello M, Facecchia I, Zuiani C, Bazzocchi M, Beltrami CA, Di Loreto C. Diagnostic accuracy of perforated compression grid approach for mammographically guided core needle biopsy of breast lesions. *Cancer Lett.* 1999 Nov 15;146(2):181-8. PubMed PMID: 10656624.

111: Bazzocchi M, Facecchia I, Zuiani C, di Loreto C, Puglisi F, Vasciaveo A. [Atypical ductal hyperplasia of the breast. Its diagnostic imaging and the role of percutaneous needle biopsy with a 14-gauge needle]. *Radiol Med.* 1999 Sep;98(3):133-7. Italian. PubMed PMID: 10575441.

112: Puglisi F, Sobrero A. [Treatment of metastatic breast carcinoma]. *Ann Ital Chir.* 1999 May-Jun;70(3):377-89. Review. Italian. PubMed PMID: 10466241.

113: Puglisi F, Di Loreto C, Beltrami CA. [Prognostic-predictive factors and therapeutic choices in invasive carcinoma of the breast]. *Ann Ital Chir.* 1999 May-Jun;70(3):335-41. Review. Italian. PubMed PMID: 10466235.

114: Delendi M, Puglisi F, Della Mea V, Riberti C, Osti M, Parodi PC. Spiradenocarcinoma: morphological and immunohistochemical features. *Adv Clin Path.* 1997 Oct;1(4):287-291. PubMed PMID: 10352492.

115: Puglisi F, Damante G, Pizzolitto S, Mariuzzi L, Guerra S, Pellizzari L, Binotto F, Beltrami CA. Combined yolk sac tumor and adenocarcinoma in a gastric stump: molecular evidence of clonality. *Cancer.* 1999 May 1;85(9):1910-6. PubMed PMID: 10223229.

116: Puglisi F, Barbone F, Damante G, Bruckbauer M, Di Lauro V, Beltrami CA, Di Loreto C. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. *Mod Pathol.* 1999 Mar;12(3):318-24. PubMed PMID: 10102618.

117: Puglisi F, Scalone S, Bazzocchi M, Fabris C, Cacitti V, Beltrami CA, Di Loreto C. Image-guided core breast biopsy: a suitable method for preoperative biological characterization of small (pT1) breast carcinomas. *Cancer Lett.* 1998 Nov 27;133(2):223-9. PubMed PMID: 10072173.

118: Silvestri F, Barillari G, Fanin R, Salmaso F, Pipan C, Falasca E, Puglisi F, Mariuzzi L, Zaja F, Infanti L, Patriarca F, Candoni A, Rogato A, Di Loreto C, Botta GA, Baccarani M. Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma. *Ann Oncol.* 1998 May;9(5):499-504. PubMed PMID: 9653490.

119: Puglisi F, Federico E, Di Loreto C. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. *Cancer.* 1998 Apr 1;82(7):1410-2. PubMed PMID: 9529038.

120: Di Loreto C, Puglisi F, Di Lauro V, Damante G, Beltrami CA. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. *Cancer Lett.* 1998 Feb 13;124(1):73-8. PubMed PMID: 9500194.



- 121: Della Mea V, Puglisi F, Bonzanini M, Forti S, Amoroso V, Visentin R, Dalla Palma P, Beltrami CA. Fine-needle aspiration cytology of the breast: a preliminary report on telepathology through Internet multimedia electronic mail. *Mod Pathol.* 1997 Jun;10(6):636-41. PubMed PMID: 9195583.
- 122: Della Mea V, Puglisi F, Forti S, Delendi M, Boi S, Mauri F, Dalla Palma P, Beltrami CA. Expert pathology consultation through the Internet: melanoma versus benign melanocytic tumours. *J Telemed Telecare.* 1997;3 Suppl 1:17-9. PubMed PMID: 9218370.
- 123: Anania G, Bazzocchi M, di Loreto C, Risaliti A, Terrosu G, Donini A, Zuiani C, Puglisi F, Bresadola F. Percutaneous large core needle biopsy versus surgical biopsy in the diagnosis of breast lesions. *Int Surg.* 1997 Jan-Mar;82(1):52-5. PubMed PMID: 9189803.
- 124: Di Loreto C, Di Lauro V, Puglisi F, Damante G, Fabbro D, Beltrami CA. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. *J Clin Pathol.* 1997 Jan;50(1):30-2. PubMed PMID: 9059352; PubMed Central PMCID: PMC499708.
- 125: Beltrami AC, Puglisi F, Di Lauro V, Scalone S, Amoroso V, Bonura S, Stamerra O, Raiti C, Di Loreto C. Biomarkers and histology of premalignant and malignant lesions. *Eur J Cancer Prev.* 1996 Oct;5(5):375-6. Review. PubMed PMID: 8972261.
- 126: Di Loreto C, Puglisi F, Rimondi G, Zuiani C, Anania G, Della Mea V, Beltrami CA. Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. *Eur J Cancer.* 1996 Sep;32A(10):1693-700. PubMed PMID: 8983276.
- 127: Puglisi F, Della Mea V, Beltrami CA. [Telepathology: from research to clinical practice]. *Pathologica.* 1996 Jun;88(3):246-7. Italian. PubMed PMID: 9045203.
- 128: Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V, Beltrami CA. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. *J Clin Pathol.* 1996 Jun;49(6):456-9. PubMed PMID: 8763257; PubMed Central PMCID: PMC500533.
- 129: Puglisi F. p53 protein expression and p53 mutation in thymic epithelial

tumors. Am J Clin Pathol. 1996 May;105(5):657-8. PubMed PMID: 8623777.

130: Puglisi F, Scalone S, DiLauro V. Angiogenesis and tumor growth. N Engl J Med. 1996 Apr 4;334(14):921. PubMed PMID: 8596588.

131: Della Mea V, Puglisi F, Forti S, Bellutta P, Finato N, Mauri F, Dalla Palma P, Beltrami CA. Telepathology through the Internet. J Telemed Telecare. 1996;2 Suppl 1:24-6. PubMed PMID: 9375082.

132: Della Mea V, Forti S, Puglisi F, Bellutta P, Finato N, Dalla Palma P, Mauri F, Beltrami CA. Telepathology using Internet multimedia electronic mail: remote consultation on gastrointestinal pathology. J Telemed Telecare. 1996;2(1):28-34. PubMed PMID: 9375039.

133: Della Mea V, Puglisi F, Beltrami CA. [The Internet for medical research]. Pathologica. 1995 Oct;87(5):485-91. Review. Italian. PubMed PMID: 8868172.

134: Puglisi F. Molecular diagnosis of neoplasms. N Engl J Med. 1995 Jul 20;333(3):194. PubMed PMID: 7791833.

135: Puglisi F, Finato N, Mariuzzi L, Marchini C, Floretti G, Beltrami CA. Microscopic thymoma and myasthenia gravis. J Clin Pathol. 1995 Jul;48(7):682-3. Erratum in: J Clin Pathol 1995 Sep;48(9):884. PubMed PMID: 7560183; PubMed Central PMCID: PMC502727.